Novel Agents in Gastroenteropancreatic Neuroendocrine Tumors
Neuroendocrine tumors (NET) are a diverse group of tumors that derive from epithelial cells with neuroendocrine differentiation. Gastroenteropancreatic neuroendocrine tumors are a subset of NET that arises in the gastrointestinal tract. Clinical symptoms and presentations vary depending on the location and hormones produced by the tumor. Treatment of advanced and metastatic gastroenteropancreatic NETs has traditionally been difficult with few systemic treatment options. In 2011, two new targeted therapies, everolimus and sunitinib were approved for treatment of pancreatic NET leading to increased interest in novel agents active in gastroenteropancreatic NETs. At the 2013 ASCO Gastrointestinal Cancers Symposium two abstracts presented new data regarding novel therapies. Lombard-Bohas et al. (Abstract #224) presented new data from the RADIANT-3 trial and Shen et al. (Abstract #322) looked at the use of octreotide in elderly patients with carcinoid syndrome.
Image: Tufts Medical Center Teddy Bear (Formerly F.A.O. Schwartz Teddy Bear). Boston, MA, USA.
Yao, James C et al. "One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States." Journal of Clinical Oncology 26.18 (2008): 3063-3072. PMID: 18565894
Oberg, K. “Gastrointestinal Neuroendocrine Tumors.” Annals of Oncology Supplement 7.(2010):vii72-80.
Yao, James C et al. "Everolimus for advanced pancreatic neuroendocrine tumors." New England Journal of Medicine 364.6 (2011): 514-523. PMID: 21306238.
Raymond, Eric et al. "Sunitinib malate for the treatment of pancreatic neuroendocrine tumors." New England Journal of Medicine 364.6 (2011): 501-513. PMID: 21306237
Rinke, Anja et al. "Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group." Journal of Clinical Oncology 27.28 (2009): 4656-4663. PMID: 19704057
Lombard-Bohas et al. “Efficacy and safety of everolimus in patients with advanced low- or intermediate-grade pancreatic neuroendocrine tumors previously treated with chemotherapy: Radiant-3 subgroup analysis.” J Clin Oncol 2012; 30 (Suppl. 34): Abstract #224.
Shen et al. “Octreotide LAR use among elderly patients with carcinoid syndrome and survival outcomes: A population-based analysis.” J Cinical Oncology 2012; 30 (Suppl. 34): Abstract #322.
Pavel, Marianne E et al. "Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study." The Lancet 378.9808 (2011): 2005-2012. PMID: 22119496
Copyright (c) 2014 Ryan Stevenson, Steven K Libutti, Muhammad Wasif Saif
This work is licensed under a Creative Commons Attribution 4.0 International License.As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.